The U.S. Food and Drug Administration on Thursday granted 510(k) clearance for Becton, Dickinson and Company’s (NYSE: BDX ) new breast biopsy system .
The FDA approved BD’s EnCor EnCompass Breast Biopsy and Tissue Removal System, which is expected to hit the market in early 2026 .
This system is designed to enhance the biopsy experience by allowing clinicians to perform procedures across various breast imaging modalities.
The EnCor EnCompass system features advanced capabilities, including high and low vacuum strengths, 360-degree sampling ability, and a choice of probes tailored for different lesion types.
Market Valuation and Performance Range
The company maintains a market capitalization of $59.10 billion. The stock’s 52-week range spans from $162.29 to $251.99.
This positive news comes during a day when major indices are also experiencing gains, with the S&P 500 up 0.50%. BDX’s rise aligns with this trend, indicating that the stock is moving in concert with broader market gains.
Key Technical Levels and Momentum Indicators
RSI (Relative Strength Index): 66.21, indicating neutral to bullish momentum MACD: 2.94 (Signal: 2.37) (Histogram: 0.58), showing bullish momentum with the MACD line above the signal line Support Level: $188.50, providing a potential floor for price movements Resistance Level: $208, representing a potential ceiling for price movementsBDX Earnings Forecast and Analyst Ratings
Analysts expect earnings per share of $2.82, down from $3.43 from the same quarter last year, and revenue of $5.15 billion, slightly down from $5.17 billion from the same quarter last year.
BD has a consensus Buy rating among analysts with an average price target of $245.93, indicating that the stock may be trading at a premium, with 50 analysts covering the stock.
BDX Scores High on Benzinga Edge Momentum
Below is the Benzinga Edge scorecard for Becton, Dickinson and Co., highlighting its strengths and weaknesses compared to the broader market:
Momentum: Bullish (Score: 35.35/100) — Stock is outperforming the broader market. Quality: Solid (Score: 28.57/100) — Balance sheet remains healthy. Value: Risk (Score: 24.16/100) — Trading at a steep premium relative to peers.The Verdict: BD’s Benzinga Edge signal reveals a classic “High-Flyer” setup. While the Momentum (35.35) confirms some positive trends, the low Value (24.16) score warns that the stock is priced for perfection — investors should remain cautious.
BDX’s Impact on Key ETFs
T. Rowe Price Capital Appreciation Equity ETF (NYSE: TCAF ): 2.94% Weight iShares US Medical Devices ETF (NYSE: IHI ): 4.44% Weight Kovitz Core Equity ETF (NYSE: EQTY ): 4.20% WeightBDX Price Action: Becton Dickinson and Co stock is up 0.25% at $207.90 at the time of publication on Thursday, according to Benzinga Pro data .
Photo: Shutterstock
BDX Becton Dickinson & Co $207.99 0.27% Overview EQTY Kovitz Core Equity ETF $28.04 0.80% IHI iShares U.S. Medical Devices ETF $62.23 -0.52% TCAF T. Rowe Price Capital Appreciation Equity ETF $38.78 0.66%This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Market News and Data brought to you by Benzinga APIs© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Add Comment | 1Posted In: Large Cap News Health Care FDA Movers Trading Ideas General AI Generated benzai disease